within Pharmacolibrary.Drugs.ATC.C;

model C03BA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.00035,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03BA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metolazone is a thiazide-like diuretic used in the treatment of hypertension and edema associated with congestive heart failure, renal dysfunction, or liver disease. It is generally administered orally and is approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Bohn, BC, et al., &amp; Shuster, JE (2019). Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction. <i>Hospital pharmacy</i> 54(6) 351–357. DOI:<a href=\"https://doi.org/10.1177/0018578718795855\">10.1177/0018578718795855</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31762481/\">https://pubmed.ncbi.nlm.nih.gov/31762481</a></p></li><li><p>Dubey, R, et al., &amp; Muthukrishnan, V (2015). Simultaneous Determination and Pharmacokinetics of Metolazone, Losartan and Losartan Carboxylic Acid in Rat Plasma by HPLC-ESI-MS-MS. <i>Journal of chromatographic science</i> 53(9) 1520–1527. DOI:<a href=\"https://doi.org/10.1093/chromsci/bmv047\">10.1093/chromsci/bmv047</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25947361/\">https://pubmed.ncbi.nlm.nih.gov/25947361</a></p></li><li><p>Tilstone, WJ, et al., &amp; Kennedy, AC (1974). Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. <i>Clinical pharmacology and therapeutics</i> 16(2) 322–329. DOI:<a href=\"https://doi.org/10.1002/cpt1974162322\">10.1002/cpt1974162322</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4853601/\">https://pubmed.ncbi.nlm.nih.gov/4853601</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03BA08;
